SUBSCRIBE
SUBSCRIBE
News   Policy

AstraZeneca PLC Goes into Battle to Defend Crestor

March 6, 2009 | 
1 min read
LONDON, March 6 (Reuters) - Lawyers at AstraZeneca will begin the long process of defending the company's all-important cholesterol drug Crestor from generic competition in a U.S. courtroom next week.
Legal Europe
AstraZeneca
MORE ON THIS TOPIC
Plan to buying new house or renovation, mortgage loan or housing expense, property maintenance or real estate insurance concept, smart businessman put jigsaw to complete or finishing house puzzle.
FDA
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
June 25, 2026
 · 
3 min read
 · 
Jef Akst
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Isometric arrow overcoming above wall on turquoise blue background. Challenge, success, development and solution concept. Flat design. Vector illustration, no transparency, no gradients
Duchenne muscular dystrophy
REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy
June 24, 2026
 · 
2 min read
 · 
Gabrielle Masson
From left to right: Julie Tierney, former deputy director of the FDA’s Center for Biologics Evaluation and Research (CBER); Ian Simon, former lead of HHS’ Office of Long Covid; Demetre Daskalakis, former director of the CDC’s National Center for Immunization and Respiratory Diseases; Jennifer Eileen Towne, chief scientific officer at Vir Biotechnology; Jared Bauer, CEO and cofounder of Seek Labs
Policy
BIO 2026: US public health as we know it is gone. Can we rebuild a better system?
June 23, 2026
 · 
4 min read
 · 
Jef Akst